IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update
30 mai 2023 07h00 HE
|
IGM Biosciences, Inc.
– Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET – MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology...
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update
12 mai 2023 09h05 HE
|
IGM Biosciences, Inc.
– Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of...
IGM Biosciences to Present at Two Upcoming Investor Conferences
02 mai 2023 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days
19 avr. 2023 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2023
13 avr. 2023 16h05 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
30 mars 2023 16h05 HE
|
IGM Biosciences, Inc.
– Encouraging initial data from IGM-8444 combination with FOLFIRI; first patient dosed in randomized trial – – Imvotamab to move forward into clinical studies in multiple autoimmune diseases – –...
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023
27 mars 2023 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference
02 févr. 2023 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors
17 janv. 2023 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
09 janv. 2023 07h00 HE
|
IGM Biosciences, Inc.
– Initial Data from Phase 1 combination with FOLFIRI shows promising activity in heavily pretreated metastatic colorectal cancer patients – – Encouraging safety profile in combination with FOLFIRI...